Contribution of IL-17–producing Γδ T Cells to the Efficacy of Anticancer Chemotherapy
Yuting Ma,Laetitia Aymeric,Clara Locher,Stephen R. Mattarollo,Nicolas Delahaye,Pablo Pereira,Laurent Boucontet,Lionel Apétoh,François Ghiringhelli,Noëlia Casares,Juan José Lasarte,Goro Matsuzaki,Koichi Ikuta,Bernard Ryffel,Kamel Benlagha,Antoine Tesnière,Nicolás Ibrahim,Julie Déchanet‐Merville,Nathalie Chaput,Mark J. Smyth,Guido Kroemer,Laurence Zitvogel
DOI: https://doi.org/10.1084/jem.20100269
2011-01-01
Abstract:By triggering immunogenic cell death, some anticancer compounds, including anthracyclines and oxaliplatin, elicit tumor-specific, interferon-γ-producing CD8(+) αβ T lymphocytes (Tc1 CTLs) that are pivotal for an optimal therapeutic outcome. Here, we demonstrate that chemotherapy induces a rapid and prominent invasion of interleukin (IL)-17-producing γδ (Vγ4(+) and Vγ6(+)) T lymphocytes (γδ T17 cells) that precedes the accumulation of Tc1 CTLs within the tumor bed. In T cell receptor δ(-/-) or Vγ4/6(-/-) mice, the therapeutic efficacy of chemotherapy was compromised, no IL-17 was produced by tumor-infiltrating T cells, and Tc1 CTLs failed to invade the tumor after treatment. Although γδ T17 cells could produce both IL-17A and IL-22, the absence of a functional IL-17A-IL-17R pathway significantly reduced tumor-specific T cell responses elicited by tumor cell death, and the efficacy of chemotherapy in four independent transplantable tumor models. Adoptive transfer of γδ T cells restored the efficacy of chemotherapy in IL-17A(-/-) hosts. The anticancer effect of infused γδ T cells was lost when they lacked either IL-1R1 or IL-17A. Conventional helper CD4(+) αβ T cells failed to produce IL-17 after chemotherapy. We conclude that γδ T17 cells play a decisive role in chemotherapy-induced anticancer immune responses.